한글목차

세계의 데스라노사이드 주사액 시장의 장래성은 병원 및 진료소 시장에서의 기회로 유망시되고 있습니다. 2025년부터 2031년까지 연평균 성장률(CAGR)은 4.5%를 보일 것으로 예측됩니다. 이 시장의 주요 성장 촉진요인은 심부전 유병률 증가, 심장 글리코사이드 수요 증가, 그리고 고령 환자 인구 증가입니다.

• Lucintel의 예측에서는 유형별로는 제네릭 의약품이 예측 기간 중에 높은 성장을 이룰 전망입니다.
• 용도별로는 병원이 더 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장이 예상됩니다.

데스라노사이드 주사액 최근 시장 동향

데스라노사이드 주사제 시장은 진화하는 임상 관행과 제약 기술 발전의 환경 속에서 방향을 모색하고 있습니다. 확립된 역할에도 불구하고, 특히 심혈관 질환 관리 및 약물 재사용(drug repurposing) 맥락에서 사용 최적화, 고유한 과제 해결, 잠재적 신규 적용 분야 탐구를 위한 지속적인 노력이 반영되고 있습니다.

• 최적화된 용량 및 모니터링 : 좁은 치료 지수(narrow therapeutic index)를 최소화하고 부작용 위험을 줄여 안전한 임상 적용을 보장하기 위해, 전해질 수치 및 신기능을 포함한 정밀한 용량 조절과 강화된 환자 모니터링에 대한 지속적인 관심이 있습니다.
• 급성 심부전 관리 강조 : 데스라노사이드 주사는 특히 신속한 작용 발현이 필요한 중증 울혈성 심부전의 급성기 관리에서 핵심적 역할을 유지합니다. 이 추세는 응급 심장학 분야에서 지속되는 중요성을 부각시킵니다.
• 신규 제형 개발 : 주로 주사제 형태이지만, 데스라노사이드를 위한 새로운 제형 및 전달 시스템 개발 기회가 존재합니다. 생체이용률 향상을 위한 설하 또는 구강 점막 정제, 지속 방출 옵션 등이 포함될 수 있으며, 이는 환자 편의성과 복약 순응도를 향상시킬 잠재력이 있습니다.
• 디지털 헬스 플랫폼 통합 : 원격 모니터링 및 원격의료와 같은 디지털 헬스 기술의 심혈관 질환 관리 분야에서의 확산은 데스라노사이드에 새로운 기회를 창출할 수 있습니다. 이러한 플랫폼과의 통합은 환자 참여도와 복약 순응도를 개선하여 지속적인 사용을 지원할 수 있습니다.

이러한 동향은 신중하게 새로운 치료 경로를 모색하면서도 급성 치료 분야의 틈새 시장을 강화함으로써 데스라노사이드 주사제 시장을 종합적으로 재편하고 있습니다. 신약 환경 속에서도 안전성 강화, 개선된 투여 방식, 잠재적 용도 전환에 대한 집중은 제약 산업 내에서 비록 특수 분야이긴 하지만 지속적인 입지를 보장합니다.

데스라노사이드 주사액 시장의 최근 동향

데스라노사이드 주사제 시장은 심혈관 의학의 광범위한 발전과 더불어 특정 심장 질환에서의 지속적인 유용성에 힘입어 최근 발전 양상을 보이고 있습니다. 이러한 발전은 신약의 등장에도 불구하고, 안전하고 효과적인 사용 보장, 공급망 안정성 확보, 기존 적응증 외 약리학적 특성 탐구에 중점을 두고 있습니다.

• 급성 심장 치료에서의 지속적인 수요 : 데스라노사이드 주사는 특히 신속한 개입이 중요한 급성 울혈성 심부전 및 특정 급성 부정맥 치료에 여전히 필수적인 약물입니다. 이는 응급 및 중환자 치료 환경에서의 수요를 유지합니다.
• 약물 부족 완화 노력 : 급성 상황에서 중요성을 고려하여, 수익성이 낮은 오래된 약물에서 흔히 발생하는 잠재적 약물 부족을 예방하고 관리하여 환자의 지속적인 접근성을 보장하기 위한 노력이 지속되고 있습니다.
• 항암 특성 연구 : 최근 연구에서는 특히 전립선암 세포에서 데스라노사이드의 항암제로서의 잠재력을 적극적으로 조사하고 있습니다. 이러한 약물 재사용 연구는 심장 효과 이상의 새로운 치료적 적용을 탐구하는 중요한 발전을 의미합니다.
• 약물감시 강조 : 데스라노사이드의 좁은 치료 범위와 약물 상호작용 및 부작용 가능성으로 인해, 안전한 투여를 보장하기 위해 임상 실무에서 약물감시와 신중한 환자 모니터링이 더욱 강조되고 있습니다.
• 글로벌 공급망 최적화 : 제조사와 유통사는 데스라노사이드 주사제의 글로벌 공급망을 최적화하여, 특히 여전히 자주 사용되는 심장 응급 치료제로 남아 있는 국가들을 포함한 다양한 지역에서 일관된 공급을 보장하기 위해 노력하고 있습니다.

이러한 발전들은 신중하게 새로운 치료 가능성을 탐구하는 동시에 급성 치료에서의 역할을 공고히 함으로써 데스라노사이드 주사제 시장에 종합적인 영향을 미치고 있습니다. 안전성, 공급망 안정성, 약물 용도 전환에 대한 강조는 심혈관 치료 환경이 계속 진화하는 가운데서도 지속적인 관련성을 보장합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 업계의 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 유형별, 데스라노사이드 주사액 시장

• 개요
• 유형별 매력 분석
• 오리지널 의약품 : 동향과 예측(2019-2031년)
• 제네릭 의약품 : 동향과 예측(2019-2031년)

제5장 용도별, 세계의 데스라노사이드 주사액 시장

• 개요
• 용도별 매력 분석
• 병원 : 동향과 예측(2019-2031년)
• 클리닉 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 지역별, 데스라노사이드 주사액 세계 시장

제7장 북미의 데스라노사이드 주사액 시장

• 개요
• 북미의 데스라노사이드 주사액 시장(유형별)
• 북미의 데스라노사이드 주사액 시장(용도별)
• 미국의 데스라노사이드 주사액 시장
• 멕시코의 데스라노사이드 주사액 시장
• 캐나다의 데스라노사이드 주사액 시장

제8장 유럽의 데스라노사이드 주사액 시장

• 개요
• 유럽의 데스라노사이드 주사액 시장(유형별)
• 유럽의 데스라노사이드 주사액 시장(용도별)
• 독일의 데스라노사이드 주사액 시장
• 프랑스 데스라노사이드 주사액 시장
• 스페인의 데스라노사이드 주사액 시장
• 이탈리아의 데스라노사이드 주사액 시장
• 영국의 데스라노사이드 주사액 시장

제9장 아시아태평양의 데스라노사이드 주사액 시장

• 개요
• 아시아태평양의 데스라노사이드 주사액 시장(유형별)
• 아시아태평양의 데스라노사이드 주사액 시장(용도별)
• 일본의 데스라노사이드 주사액 시장
• 인도의 데스라노사이드 주사액 시장
• 중국의 데스라노사이드 주사액 시장
• 한국의 데스라노사이드 주사액 시장
• 인도네시아의 데스라노사이드 주사액 시장

제10장 기타 지역의 데스라노사이드 주사액 시장

• 개요
• 기타 지역의 데스라노사이드 주사액 시장(유형별)
• 기타 지역의 데스라노사이드 주사액 시장(용도별)
• 중동의 데스라노사이드 주사액 시장
• 남미의 데스라노사이드 주사액 시장
• 아프리카의 데스라노사이드 주사액 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 구매자의 협상력
  • 공급기업의 협상력
  • 대체품의 위협
  • 신규 참가업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 유형별 성장 기회
  • 용도별 성장 기회
• 세계의 데스라노사이드 주사액 최근 시장 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 합병, 인수, 계약, 제휴, 합작 사업

제13장 밸류체인에서 주요 기업 프로파일

• Competitive Analysis
• ShanghaizhaoHui Pharmaceutical
• Shanghai Xudong Haipu Pharmaceutical
• Chengdu Brilliant Pharmaceutical
• Viwit Pharmaceuticals
• Ryvis Pharma

제14장 부록

• 도표 일람
• 표 일람
• 조사 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• 미국에 대해
• 미국 문의

영문목차

The future of the global deslanoside injection market looks promising with opportunities in the hospital and clinic markets. The global deslanoside injection market is expected to grow with a CAGR of 4.5% from 2025 to 2031. The major drivers for this market are the increasing prevalence of heart failure, the rising demand for cardiac glycosides, and the growing elderly patient population.

• Lucintel forecasts that, within the type category, generic drug is expected to witness higher growth over the forecast period.
• Within the application category, hospital is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Deslanoside Injection Market

The deslanoside injection market is navigating a landscape of evolving clinical practices and pharmaceutical advancements. Despite its established role, emerging trends reflect a continuous effort to optimize its use, address inherent challenges, and explore potential new applications, particularly in the context of cardiovascular disease management and drug repurposing.

• Optimized Dosage and Monitoring: There is a continued focus on precise dosage adjustment and enhanced patient monitoring, including electrolyte levels and renal function, to minimize deslanoside's narrow therapeutic index and reduce the risk of adverse effects, ensuring safer clinical application.
• Emphasis on Acute Heart Failure Management: Deslanoside injection maintains its critical role in the acute management of severe congestive heart failure, particularly when rapid onset of action is required. This trend highlights its continued relevance in emergency cardiology.
• Drug Repurposing for Oncology: Emerging research suggests deslanoside, like other cardiac glycosides, may exhibit anticancer activity. This trend explores its potential repurposing for prostate cancer and other malignancies, offering a novel avenue for market growth beyond its traditional cardiac indications.
• Development of Novel Formulations: While primarily an injectable, opportunities exist for developing novel formulations and delivery systems for deslanoside. This could include sublingual or buccal tablets to improve bioavailability or sustained-release options, potentially enhancing patient convenience and adherence.
• Integration into Digital Health Platforms: The increasing adoption of digital health technologies, such as remote monitoring and telemedicine, in cardiovascular disease management could create new opportunities for deslanoside. Integration into these platforms could improve patient engagement and adherence, supporting its continued use.

These trends are collectively reshaping the deslanoside injection market by reinforcing its niche in acute care, while cautiously exploring new therapeutic avenues. The focus on safety, improved delivery, and potential repurposing, amidst a landscape of newer drugs, ensures its continued, albeit specialized, presence in the pharmaceutical industry.

Recent Developments in the Deslanoside Injection Market

The deslanoside injection market has seen recent developments driven by its ongoing utility in specific cardiac conditions, alongside the broader evolution of cardiovascular medicine. These advancements focus on ensuring its safe and effective use, addressing supply chain stability, and exploring its pharmacological properties beyond its traditional indications, despite the advent of newer therapeutic agents.

• Sustained Demand in Acute Cardiac Care: Deslanoside injection continues to be a vital medication for acute congestive heart failure and certain rapid arrhythmias, especially where prompt intervention is critical. This sustains its demand in emergency and critical care settings.
• Focus on Drug Shortage Mitigation: Given its importance in acute situations, there is an ongoing focus on preventing and managing potential drug shortages of deslanoside injection, often a challenge for older, less profitable medications, to ensure continuous patient access.
• Research into Anticancer Properties: Recent studies are actively investigating deslanoside's potential as an anticancer agent, particularly in prostate cancer cells. This research into drug repurposing represents a significant development, exploring new therapeutic applications beyond its cardiac effects.
• Emphasis on Pharmacovigilance: Due to deslanoside's narrow therapeutic index and potential for drug interactions and adverse effects, there is a heightened emphasis on pharmacovigilance and careful patient monitoring in clinical practice to ensure its safe administration.
• Global Supply Chain Optimization: Manufacturers and distributors are working to optimize global supply chains for deslanoside injection, ensuring consistent availability across different regions, particularly in countries where it remains a frequently used cardiac emergency drug.

These developments are collectively impacting the deslanoside injection market by solidifying its role in acute care, while cautiously exploring new therapeutic potential. The emphasis on safety, supply chain stability, and drug repurposing ensures its ongoing relevance, even as the cardiovascular treatment landscape continues to evolve.

Strategic Growth Opportunities in the Deslanoside Injection Market

The deslanoside injection market, while mature, presents strategic growth opportunities by focusing on its unique pharmacological properties and addressing specific clinical needs. By leveraging its rapid onset and established efficacy in acute settings, alongside exploring novel therapeutic avenues, manufacturers can ensure its continued relevance and potentially expand its market footprint in a competitive landscape.

• Acute Decompensated Heart Failure: Capitalizing on deslanoside's rapid inotropic effect for intravenous administration in acute decompensated heart failure is a key growth opportunity, particularly in emergency and critical care settings where immediate improvement in cardiac function is paramount.
• Rapid Ventricular Rate Control in Atrial Fibrillation: For patients with rapid ventricular response in atrial fibrillation where other agents are contraindicated or ineffective, deslanoside injection offers a valuable growth opportunity due to its ability to quickly slow the heart rate and improve hemodynamics.
• Repurposing in Oncology (e.g., Prostate Cancer): Pursuing clinical trials and research for deslanoside's potential anticancer effects, especially against prostate cancer cells, represents a significant growth opportunity for drug repurposing, potentially opening entirely new therapeutic markets for the drug.
• Role in Resource-Limited Settings: In developing economies or resource-limited settings where newer, more expensive cardiovascular drugs may not be readily available, deslanoside's cost-effectiveness and established efficacy for acute conditions present a vital growth opportunity for essential medicine provision.
• Niche Use in Pediatric Cardiology: While requiring careful dosing, deslanoside may find specific, though limited, growth opportunities in pediatric cardiology for certain acute heart failure or arrhythmia conditions in children, where its rapid action can be clinically advantageous.

These strategic growth opportunities are impacting the deslanoside injection market by reinforcing its critical role in acute care settings and exploring promising new therapeutic avenues. By focusing on these specific applications, manufacturers can ensure its continued demand, contribute to public health, and potentially expand its overall market value.

Deslanoside Injection Market Driver and Challenges

The deslanoside injection market is influenced by a blend of drivers supporting its continued use and significant challenges impeding broader expansion. Major drivers include its rapid action in acute cardiac emergencies and its established clinical efficacy. However, the market faces hurdles such as its narrow therapeutic window, the risk of drug interactions, and the emergence of newer, often safer, cardiovascular drugs.

The factors responsible for driving the deslanoside injection market include:

1. Rapid Onset of Action: Deslanoside's quick onset of action when administered intravenously makes it invaluable for managing acute cardiac emergencies, such as severe congestive heart failure, where immediate therapeutic effect is crucial for patient stabilization.

2. Established Clinical Efficacy: Despite the development of newer drugs, deslanoside has a long history of proven efficacy in improving myocardial contractility and controlling ventricular rates in specific cardiac arrhythmias, maintaining its clinical relevance.

3. Affordability and Accessibility (in some regions): As an older, generic drug, deslanoside injection is often more affordable and readily accessible compared to newer, patented cardiovascular medications, particularly in developing economies, driving its continued use.

4. Use in Specific Clinical Scenarios: Deslanoside remains a valuable option in specific clinical scenarios where other treatments might be ineffective or contraindicated, ensuring its continued demand as a niche, yet essential, therapeutic agent.

5. Global Burden of Cardiovascular Diseases: The increasing global prevalence of cardiovascular diseases, including heart failure and arrhythmias, contributes to an underlying demand for various cardiac medications, including deslanoside for acute management.

Challenges in the deslanoside injection market are:

1. Narrow Therapeutic Index and Toxicity Risk: Deslanoside has a very narrow therapeutic window, meaning the effective dose is close to the toxic dose. This necessitates careful monitoring and dosage adjustment, increasing the risk of adverse effects and limiting its widespread use.

2. Drug Interactions and Adverse Effects: Deslanoside is prone to numerous drug interactions with commonly prescribed medications and can cause significant adverse effects, including arrhythmias and gastrointestinal issues, requiring meticulous patient management.

3. Competition from Newer, Safer Drugs: The market faces significant competition from a wide range of newer cardiovascular drugs (e.g., beta-blockers, ACE inhibitors, ARBs) that often offer a broader therapeutic window, fewer side effects, and more convenient dosing, leading to a decline in deslanoside's overall market share.

The market is driven by its acute efficacy and affordability, securing its place in specific cardiac emergencies. However, its narrow therapeutic index, interaction risks, and competition from newer drugs present significant challenges. Sustained market presence hinges on careful clinical application and ongoing efforts to address its inherent limitations.

List of Deslanoside Injection Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies deslanoside injection companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the deslanoside injection companies profiled in this report include-

• ShanghaizhaoHui Pharmaceutical
• Shanghai Xudong Haipu Pharmaceutical
• Chengdu Brilliant Pharmaceutical
• Viwit Pharmaceuticals
• Ryvis Pharma

Deslanoside Injection Market by Segment

The study includes a forecast for the global deslanoside injection market by type, application, and region.

Deslanoside Injection Market by Type [Value from 2019 to 2031]:

• Original Drug
• Generic Drug

Deslanoside Injection Market by Application [Value from 2019 to 2031]:

• Hospital
• Clinic
• Others

Deslanoside Injection Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Deslanoside Injection Market

The deslanoside injection market, primarily used for acute congestive heart failure and cardiac arrhythmias, is experiencing evolving dynamics. While newer cardiovascular drugs have emerged, deslanoside retains a niche due to its rapid onset and specific mechanism of action. Recent developments across major economies reflect shifts in clinical practice, manufacturing focus, and ongoing challenges related to its inherent properties and therapeutic alternatives.

• United States: The US market for deslanoside injection sees its use driven by acute cardiac emergencies and specific guidelines. Recent developments include continued careful monitoring for adverse effects and drug interactions due to its narrow therapeutic index, and a focus on maintaining supply chain stability for this essential, albeit specialized, medication, amidst a broader shift to newer cardiovascular treatments.
• China: China's deslanoside injection market is influenced by its large patient population and domestic pharmaceutical production capabilities. Recent developments include a focus on ensuring local production and supply of essential medicines, and a growing emphasis on managing drug shortages which can impact the availability of older, low-cost drugs like deslanoside, despite their clinical utility.
• Germany: The German market for deslanoside injection aligns with its strong healthcare infrastructure and emphasis on high-quality pharmaceuticals. Recent developments include its continued use in specific acute cardiac settings, alongside a broader trend of increasing R&D in the pharmaceutical sector and rising prevalence of chronic diseases, though newer treatments often take precedence.
• India: India's deslanoside injection market is characterized by increasing local production and a growing healthcare sector. Recent developments include efforts to ensure the availability of essential cardiac medications, and an expanding focus on managing cardiovascular diseases, driving demand for various treatments, including deslanoside for acute situations, as part of its extensive healthcare system.
• Japan: Japan's market for deslanoside injection is shaped by its advanced healthcare system and stringent quality control. Recent developments likely include adherence to its pharmacopoeia standards for quality assurance, and a focus on clinical efficacy and patient safety given its potent nature, while research may explore its role in specific cardiac conditions.

Features of the Global Deslanoside Injection Market

• Market Size Estimates: Deslanoside injection market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Deslanoside injection market size by type, application, and region in terms of value ($B).
• Regional Analysis: Deslanoside injection market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the deslanoside injection market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the deslanoside injection market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the deslanoside injection market by type (original drug and generic drug), application (hospital, clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Deslanoside Injection Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Original Drug: Trends and Forecast (2019-2031)
• 4.4 Generic Drug: Trends and Forecast (2019-2031)

5. Global Deslanoside Injection Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital: Trends and Forecast (2019-2031)
• 5.4 Clinic: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Deslanoside Injection Market by Region

7. North American Deslanoside Injection Market

• 7.1 Overview
• 7.2 North American Deslanoside Injection Market by Type
• 7.3 North American Deslanoside Injection Market by Application
• 7.4 United States Deslanoside Injection Market
• 7.5 Mexican Deslanoside Injection Market
• 7.6 Canadian Deslanoside Injection Market

8. European Deslanoside Injection Market

• 8.1 Overview
• 8.2 European Deslanoside Injection Market by Type
• 8.3 European Deslanoside Injection Market by Application
• 8.4 German Deslanoside Injection Market
• 8.5 French Deslanoside Injection Market
• 8.6 Spanish Deslanoside Injection Market
• 8.7 Italian Deslanoside Injection Market
• 8.8 United Kingdom Deslanoside Injection Market

9. APAC Deslanoside Injection Market

• 9.1 Overview
• 9.2 APAC Deslanoside Injection Market by Type
• 9.3 APAC Deslanoside Injection Market by Application
• 9.4 Japanese Deslanoside Injection Market
• 9.5 Indian Deslanoside Injection Market
• 9.6 Chinese Deslanoside Injection Market
• 9.7 South Korean Deslanoside Injection Market
• 9.8 Indonesian Deslanoside Injection Market

10. ROW Deslanoside Injection Market

• 10.1 Overview
• 10.2 ROW Deslanoside Injection Market by Type
• 10.3 ROW Deslanoside Injection Market by Application
• 10.4 Middle Eastern Deslanoside Injection Market
• 10.5 South American Deslanoside Injection Market
• 10.6 African Deslanoside Injection Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Deslanoside Injection Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 ShanghaizhaoHui Pharmaceutical
  • Company Overview
  • Deslanoside Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Shanghai Xudong Haipu Pharmaceutical
  • Company Overview
  • Deslanoside Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Chengdu Brilliant Pharmaceutical
  • Company Overview
  • Deslanoside Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Viwit Pharmaceuticals
  • Company Overview
  • Deslanoside Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Ryvis Pharma
  • Company Overview
  • Deslanoside Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us